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Abbreviation: Cancer/testis antigen; CT antigen, draining lymph nodes; dLN, 
mutated MAP kinase, ERK2; mERK2, 5-fluorouracil; 5-FU, Immune complex; 
IC. 
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 Abstract 
 
Monoclonal antibody (mAb) therapy against tumor antigens expressed on the 
tumor surface is associated with clinical benefit. However, many tumor 
antigens are intracellular molecules that generally would not be considered 
suitable targets for mAb therapy. In this study, we provide evidence 
challenging this view through an investigation of the efficacy of mAb directed 
against NY-ESO-1, a widely expressed immunogen in human tumors that is 
expressed intracellularly rather than on the surface of cells. On their own, 
NY-ESO-1 mAb could neither augment antigen-specific CD8+ T cell induction 
nor cause tumor eradication. To facilitate mAb access to intracellular target 
molecules, we combined anti-NY-ESO-1 mAb with anti-cancer drugs to 
accentuate the release of intracellular NY-ESO-1 from dying tumor cells. 
Strikingly, combination therapy induced a strong anti-tumor effect that was 
accompanied by the development of NY-ESO-1-specific effector/memory 
CD8+ T cells that were not elicited by single treatments alone. The 
combinatorial effect was also associated with upregulation of maturation 
markers on dendritic cells, consistent with the organization of an effective 
antitumor T cell response. Administration of Fc-depleted Fab mAb or 
combination treatment in Fcγ receptor-deficient host mice abolished the 
therapeutic effect. Together, our findings demonstrate that intracellular tumor 
antigens can be captured by mAbs and engaged in an efficient induction of 
CD8+ T cell responses, greatly expanding the possible use of mAb for passive 
cancer immunotherapy. 
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 Introduction 
 
With the molecular identification of tumor antigens recognized by the human 
immune system, antigen-specific immunotherapy for cancers has been 
developed and is explored in the clinic (1-3). Particularly, mAbs that recognize 
surface antigens, such as trastuzumab (anti-Her2/neu) and rituximab 
(anti-CD20), as a single agent or in combination with chemotherapy, are used 
in the clinic for frontline or salvage therapy and have resulted in objective and 
durable clinical responses (3-5). One of the major therapeutic mechanisms of 
mAb is considered to be the selective interruption of vital signaling pathways in 
which the targeted antigens are critically involved (3, 5). In addition, there is 
accumulating evidence that mAb therapy also works through Ab-dependent 
cellular cytotoxicity (ADCC) by NK cells or through the activation of 
complement, both of which depend on the Fc portion of the mAbs (6-9). 
Furthermore, Fc receptor-mediated uptake of immune complexes results in 
activation of APCs and facilitates cross-presentation of those antigens to 
tumor-specific CD8+ T cells and inhibition of tumor growth, as was shown 
recently in HER2/neu and melanoma differentiation antigen tyrosinase-related 
protein-1 (Trp1; gp75) models (10-13). 
However, many well-characterized tumor-associated antigens including 
cancer/testis (CT) antigens are intracellular antigens and thus not accessible 
for Abs (14-16). An exception is mAb TA99, which targets gp75 and was 
shown to induce NK and CD4+ T cell dependent anti-tumor responses in vivo 
(17). However, the fact that gp75 is expressed both on the cell surface as well 
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as intracellularly makes it difficult to defining the precise targets for the 
anti-tumor responses induced by mAb TA99 (12, 17). 
NY-ESO-1, a CT antigen discovered by SEREX (serological 
identification of antigens by recombinant expression cloning) using the serum 
of an esophageal cancer patient, is frequently expressed in cancer cells of 
various tissue origins, but not in normal somatic cells except for germ cells in 
the testis (2, 18). Spontaneous cellular and humoral immune responses 
against NY-ESO-1 are found in cancer patients, which underscores its 
immunogenicity (2, 18). It has an intracellular location and lacks cell surface 
expression (2, 18), thus curtails it from being a candidate of mAb therapy. 
Interestingly, NY-ESO-1 protein/ IgG Ab complexes (immune complexes: IC) 
are efficiently cross-presented to the MHC-class I pathway (19, 20) and there 
is a close correlation between Ab and CD8+ T cell responses (2, 21), 
suggesting that NY-ESO-1-specific CD8+ T cell induction by cross-priming in 
vivo is associated with the induction of specific Abs. These data prompted us 
to analyze the possibility whether mAb therapy could be applied to an 
intracellular molecule NY-ESO-1 and inhibit tumor growth by enhancing CD8+ 
T cell induction. 
 We have established syngeneic tumor models in BALB/c mice using 
CT26 colon carcinoma cells and CMS5a sarcoma cells that are stably 
transfected with NY-ESO-1 (22, 23). Using these models, we addressed 
whether NY-ESO-1 mAb combined with chemotherapy augmented 
NY-ESO-1-specific CD8+ T cell induction and inhibited tumor growth. 
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Materials and Methods 
 
Mice 
Female BALB/c mice and BALB/cnu/nu mice were obtained from SLC Japan or 
Jackson laboratory and used at 7-10 weeks of age. BALB/c mice deficient in 
the γ chain subunit of Fc receptors were obtained from Taconic and used at 
7-10 weeks of age. Mice were maintained in accordance with the NIH and 
American Association of Laboratory Animal Care regulations. The 
experimental protocol was approved by the Ethics Review Committee for 
Animal Experimentation of Mie University Graduate School of Medicine and by 
the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and 
Use Committee. 
 
Tumors 
CT26 is a colon epithelial tumor derived by intrarectal injections of 
N-nitroso-N-methylurethane in BALB/c mice (24). CT26 expressing NY-ESO-1 
(CT26-NY-ESO-1) was established as described (2, 22, 23). CMS5a is a 
subcloned cell line obtained from CMS5 (25). CMS5a-NY-ESO-1 was 
established as described (22). 
 
Antibodies and reagents 
Anti-NY-ESO-1 mAbs [E978 (mouse IgG1) recognizing NY-ESO-171-90, ES121 
(mosue IgG1) recognizing NY-ESO-191-110, 219-510 (mouse IgG1) recognizing 
NY-ESO-121-40, [Supplemental Figure 3, (26)], anti-CD4 (GK1.5, rat IgG2b), 
anti-CD8 (19/178, mouse IgG2a) and anti-MAGE-A4 (MCV1, mouse IgG1) 
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were purified from hybridoma supernatant by protein G affinity 
chromatography. The Fab fragment of E978 was generated using the 
ImmunoPure Fab Preparation Kit (Thermo Fisher Scientific). Anti-CD8 (53-6.7), 
anti-CD45RB (16A), anti-CD80 (16-10A1), anti-CD86 (GL-1), anti-CD40 (3/23), 
anti-IFN-γ (XMG1.2), anti-CD62L (MEL-14), anti-CD11c (HL3), anti-TNF-α 
(MP6-XT22) and anti-mouse IgG1 (A85-1) mAbs were purchased from BD 
Biosciences, Biolegend or eBioscience. PE-labeled NY-ESO-181-88-Dd 
tetramers were provided from Drs. P. Guillaume and I. Luescher (Ludwig 
Institute Core Facility, Lausanne, Switzerland). An anti-NY-ESO-1 human 
IgG1 mAb (12D7) was obtained from CT Atlantic (Schlieren, Switzerland). p63 
(T) peptide TYLPTNASL (27), AH-1138-147 peptide SPSYVHQF (28) and 
NY-ESO-181-88 peptide RGPESRLL (23) were purchased from Operon 
Biotechnologies (Tokyo, Japan), BioSynthesis (Lewisville, TX) and Sigma. 
 
Chemotherapeutic agents 
5-fluorouracil (5-FU, Kyowa Hakko Kirin, Tokyo, Japan), doxorubicin (Kyowa 
Hakko Kirin), CPT-11 (Yakult, Tokyo, Japan), paclitaxel (Bristol-Myers Squibb), 
cyclophosphamide (Shionogi, Osaka, Japan) were injected intraperitoneally as 
indicated. 
 
Tumor challenge  
Mice were inoculated with 0.5 - 1 x 106 CT26-NY-ESO-1 cells, 1 x 106 
CMS5a-NY-ESO-1, or 1 x 106 CT26-MAGE-A4 cells in the right hind flank 
subcutaneously. Mice were monitored three times a week and were sacrificed 
when tumors reached >20 mm. 
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Staining and flow cytometry 
To collect tumor infiltrating T cells, tumors were minced and treated with 
1 mg/mL of collagenase IA (Sigma) in HBSS for 90 min at room temperature. 
 Cells harvested from draining lymph node (dLN) and tumors were 
stained for surface markers in PBS with 0.5% FBS for 15 min at 4ºC. For 
intracellular cytokine staining, 1-3 x 106 cells from tumors or dLN were cultured 
with peptide for 5h at 37 ºC, and GolgiPlug was added for the last 4h of culture. 
These cells were stained for surface markers and intracellularly with 
APC-conjugated anti-IFN-γ and PE-conjugated anti-TNF-α mAbs after 
permiabilization and fixation using Cytofix/Cytoperm Kit (BD Bioscience). Dead 
cells were excluded by LIVE/DEAD Fixable Dead Cell Stain Kits (Invitrogen). 
Cells were analyzed on FACSCanto or FACScalibur (BD Bioscience) and 
FlowJo software (Tree Star, Ashland, OR). 
  
Fluorescent immunohistochemistry 
Three μm tissue sections prepared from fresh frozen tumor specimens were 
fixed with ice-chilled acetone for 15 minutes. Alexa 488-labeled anti-human 
IgG Ab (Invitrogen) was applied and incubated at room temperature for 2 hrs. 
For double immunolabeling, sections were fixed with 3% paraformaldehyde for 
15 minutes, incubated with anti-cleaved caspase 3 (Cell signaling technology, 
Beverly, MA) at room temperature for 2hrs, and then incubated 
Alexa-488-labeled anti-human IgG antibody and Alexa-568-labeled anti-rabbit 
IgG Ab (Invitrogen) at room temperature for 2hrs. Sections were rinsed with 
PBS, counterstained with 4',6-diamidino-2-phenylindole (DAPI) and mounted. 
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Images were captured using x40 magnification objective by Zeiss AxioCam 
system (Carl Zeiss, Oberkochen, Germany). 
 
Statistical analysis 
Tumor curves were assessed by one-way ANOVA with a Bonferroni multiple 
comparisons posttest. Single measurement comparison between two groups 
was evaluated by two-sided Student’s t test. P values < 0.05 were considered 
statistically significant. 
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Results 
 
Establishment of CT26-NY-ESO-1 
We established a syngeneic colon carcinoma model (CT26-NY-ESO-1) with 
stable NY-ESO-1 expression (2, 22, 23). NY-ESO-1 expression in 
CT26-NY-ESO-1 cells was exclusively intracellular, and no NY-ESO-1 protein 
was detected on the cell surface (Supplemental Figure 1A), consistent with the 
expression of NY-ESO-1 protein in human cancer cells (2). These 
CT26-NY-ESO-1 cells maintained the same tumor growth capacity as their 
parental CT26 cells in both wild-type Balb/c and C.B-17 Scid mice, indicating 
that there was no alteration of tumorigenicity caused by the NY-ESO-1 
transfection (Supplemental Figure 1B). When BALB/c mice were inoculated 
with CT-26-NY-ESO-1 cells, spontaneous Ab and CD8+ T cell responses were 
detected after 7 days and increased thereafter (Supplemental Figure 1C and 
1D). These spontaneous immune responses closely paralleled spontaneous 
NY-ESO-1-specific immune responses found in humans (2). 
We used this tumor model to explore the anti-tumor effects of mAbs 
against NY-ESO-1 alone and in combination with an anti-cancer drug. To 
select anti-cancer drugs suitable for this model, we examined the anti-tumor 
capacity of several anti-cancer drugs (5-FU, CPT-11, Paclitaxel, and 
Doxorubicin) against CT26-NY-ESO-1. Of the four drugs, 5-FU exhibited a 
significant anti-tumor effect (Supplemental Figure 2A). When 
CT-26-NY-ESO-1 cells were cultured with 5-FU, NY-ESO-1 protein was 
released from CT-26-NY-ESO-1 cells into the culture supernatant, but not from 
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parental CT26 cells, (Supplemental Figure 2B). Based on these data, we 
chose 5-FU for our further experiments. 
 
Combination treatment with anti-NY-ESO-1 mAb and 5-FU results in 
augmented tumor growth inhibition. 
BALB/c mice were inoculated with CT26-NY-ESO-1 and were injected with 
5-FU (75 mg/kg) and anti-NY-ESO-1 mAb (clone; E978, 100 µg, two days 
after 5-FU injection) when the tumor was palpable (around 25 mm2). 
Treatment was repeated after one week. The combination treatment with 
anti-NY-ESO-1 mAb and 5-FU exhibited a significantly augmented anti-tumor 
effect and longer survival compared with control mice or mice that had 
received either 5-FU or anti-NY-ESO-1 mAb alone (Figure 1A and 1B). This 
augmented anti-tumor effect was also observed when another anti-NY-ESO-1 
mAb (clone; ES121, 100 µg) was used, but not with a control mAb, against 
another immunogenic cancer/testis antigen MAGE-A4, which is not expressed 
in the CT26-NY-ESO-1 cells (Figure 1C and 1D). In contrast, combination 
treatment with anti-MAGE-A4 mAb (clone; MCV1, 100 µg), but not control Ab 
and 5-FU exhibited an augmented anti-tumor effect against CT-26-MAGE-A4 
(Figure 1E). To show the effect of this combination treatment is not limited to 
the CT26, we examined the anti-tumor effect using CMS5a fibrosarcoma cells. 
BALB/c mice were inoculated with CMS5a-NY-ESO-1 and were injected with 
doxorubicin (50 μl intratumoral injection, 0.25 mM) and anti-NY-ESO-1 mAb. 
As systemic administration of doxorubicin did not induce effective killing of 
CMS5a-NY-ESO-1, we employed an intratumoral injection method. This 
combination treatment with anti-NY-ESO-1 mAb (but not an isotype control Ab) 
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and doxorubicin exhibited a significantly augmented anti-tumor effect as well 
(Figure 1F). These data suggest that the augmented anti-tumor effect is an 
antigen-specific phenomenon and that this combination treatment could be 
applicable to a broader range of intracellular antigens and tumors. 
We next investigated whether a cocktail of two different anti-NY-ESO-1 
mAbs (E978 50 µg and ES121 50 µg) that recognize two different 
non-overlapping epitopes on the NY-ESO-1 protein (Supplemental Figure 3) 
further augmented anti-tumor effects. We observed no additive anti-tumor 
effects when mice were treated with the combination of two different 
anti-NY-ESO-1 mAbs and 5-FU compared with mice treated with a single 
anti-NY-ESO-1 mAb and 5-FU (Figure 1G). 
 
Augmented tumor growth inhibition by combination treatment with 
anti-NY-ESO-1 mAb and 5-FU is dependent on CD8+ T cells. 
To gain insight into the cellular components involved in the augmented 
anti-tumor effects by the combination treatment, we initially examined the role 
of T cells using BALB/cnu/nu mice. BALB/cnu/nu mice were inoculated with 
CT26-NY-ESO-1 and combination treatment with 5-FU and anti-NY-ESO-1 
mAb was initiated when the tumor was palpable. The augmented anti-tumor 
effect by the combination treatment in wild-type BALB/c mice was abrogated in 
BALB/cnu/nu mice (Figure 2A). 
Given the critical role of T cells in this augmentation of anti-tumor 
effects, we next explored the outcome of CD4+ / CD8+ T cell depletion on the 
augmented anti-tumor effect. BALB/c mice bearing CT26-NY-ESO-1 tumors 
were injected with 5-FU and anti-NY-ESO-1 mAb and received anti-CD4 (day 
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7, 14 and 21) or anti-CD8 mAb (day 7 and 21). The depletion of CD8+ T cells 
totally abolished the augmented anti-tumor effects (Figure 2B). In contrast, 
CD4+ T cell depletion did not affect the augmented anti-tumor effects (Figure 
2B). 
 
Combination treatment with anti-NY-ESO-1 mAb and 5-FU enhances 
NY-ESO-1-specific CD8+ T cell induction. 
Considering a critical role of CD8+ T cells, we examined NY-ESO-1-specific T 
cells in dLN. BALB/c mice were inoculated with CT26-NY-ESO-1 and received 
the combination treatment. dLN and tumors were harvested on day 14-16 and 
cells were incubated with NY-ESO-181-88 (23) or control peptide, and cytokine 
secretion was analyzed. Combination treatment with anti-NY-ESO-1 mAb and 
5-FU elicited significantly higher numbers of NY-ESO-1-specific CD8+ T cells 
producing IFN-γ and/or TNF-α compared with 5-FU alone (Figure 3A). Further, 
there was a trend to higher numbers of NY-ESO-1-specific CD8+ T cells in 
tumors treated with the combination treatment compared with those treated 
with 5-FU alone (Figure 3C). 
To explore further differences in NY-ESO-181-88-specific CD8+ T cells, 
the effector/memory status was analyzed. The frequency of 
NY-ESO-1-specific CD8+ T cells as measured by CD8+NY-ESO-1/Dd tetramer+ 
T cells was higher in mice treated with the combination therapy as compared 
to mice treated with 5-FU alone, confirming the data from the intracellular 
cytokine assays. The frequency of effector/memory (CD62LlowCD45RBlow) T 
cells was higher in mice treated with the combination treatment (Figure 3B). In 
contrast, frequency of naive (CD62LhighCD45RBhigh) T cells was higher in mice 
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treated with 5-FU alone, indicating that the combination treatment efficiently 
activated antigen-specific CD8+ T cells. 
 
Therapeutically effective antigen spreading is observed in mice treated 
with the combination treatment. 
Certain immunization strategies result in the development of an immune 
response against tumor antigens that are not contained in the vaccine but are 
found in tumor cells, a phenomenon known as antigen spreading (22, 29, 30). 
Therefore, we explored whether the combination treatment resulted in the 
development of an immune response against other antigens expressed in 
tumor cells. As we employed CT26 tumors, we examined CD8+ T cells 
recognizing AH-1 peptide, which is derived from the envelope protein (gp70) of 
an endogenous ecotropic murine leukemia provirus expressed by CT26 and 
previously shown to be a target of CD8+ T cells (28). Mice bearing 
CT26-NY-ESO-1 received treatment with anti-NY-ESO-1 mAb and 5-FU. 
Given that antigen spreading is observed after the antigen release from killed 
tumor cells, AH-1-specific CD8+ T cell induction was analyzed at later time 
point (day 24). Significantly higher numbers of AH-1-specific CD8+ T cells was 
detected in mice treated with anti-NY-ESO-1 mAb and 5-FU compared with 
mice treated with 5-FU alone (Figure 4). 
 
The Ab Fc portion is required for the augmented anti-tumor effect by the 
combination treatment. 
We next explored the mechanism(s) of the augmented anti-tumor effect and 
the differences of NY-ESO-181-88-specific CD8+ T cells. MAb therapy can 
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exhibit immunostimulatory effects through the Fc portion of a mAb (7, 8). We 
investigated whether the augmented anti-tumor effect by combination 
treatment depended on the Fc portion of the mAb. BALB/c mice bearing 
CT26-NY-ESO-1 tumors were injected with 5-FU (day 7 and 14) and intact Ab 
or an Fc-depleted form of the anti-NY-ESO-1 mAb (day 9 and 16). The 
anti-tumor effect induced by the combination treatment with the intact 
anti-NY-ESO-1 mAb and 5-FU was totally abolished when Fab antibodies 
were administered (Figure 5A). We further examined the critical role of the Fc 
portion for this augmented anti-tumor effect by the combination treatment 
using activating Fcγ receptor knockout mice (Fcer1g-/- mice). In these mice, we 
did not observe the augmented anti-tumor effect by the combination treatment 
compared with mice treated with 5-FU alone (Figure 5B), confirming the critical 
role of the Ab Fc portion for this augmented anti-tumor effect. 
 
Accumulation of Ab to tumor sites by combination treatment 
Given the importance of the Fc portion and the antigen-Ab IC formation for an 
enhancement of CD8+ T cells (19-21), we examined the accumulation of the 
anti-NY-ESO-1 mAb to tumor sites for assessing the in vivo formation of 
antigen-Ab IC. To this purpose, we utilized a human anti-NY-ESO-1 mAb to 
detect and visualize the accumulation of anti-NY-ESO-1 mAb at the tumor 
sites. BALB/c mice bearing CT26-NY-ESO-1 received 5-FU and human 
anti-NY-ESO-1 mAb two days later. Tumors were removed several time points 
after the mAb injection. Anti-NY-ESO-1 mAb accumulated in CT26-NY-ESO-1 
tumors after 24 hrs and maintained thereafter when given in combination with 
5-FU (Figure 6A and 6B). In contrast, the accumulation of anti-NY-ESO-1 mAb 
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in the tumors was lower without 5-FU treatment (Figure 6A and 6B). We next 
tested whether the released NY-ESO-1 protein localized around the area of 
5-FU-induced cell death. Anti-NY-ESO-1 mAb accumulated around the 
apoptotic area detected by cleaved caspase 3 staining (Figure 6B), suggesting 
that 5-FU accentuated the natural release of intracellular NY-ESO-1 from 
dying tumor cells subsequently resulting in an increased accumulation of 
anti-NY-ESO-1 mAb in tumors and the formation of antigen-Ab IC. 
 
Formation of antigen-Ab IC in-vivo by the combination treatment induces 
sufficient maturation of DCs for tumor eradication. 
We next analyzed the role of DCs for this augmentation of anti-tumor effects. 
The activation status (CD80, CD86, MHC class II and CD40) of CD11c+ DCs at 
dLN after treatment was examined. The expression level of CD80, CD86, 
MHC class II and CD40 in DCs was significantly enhanced in mice that 
received the combination treatment with anti-NY-ESO-1 mAb and 5-FU 
compared to mice treated with 5-FU alone (Figure 6C). 
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Discussion 
 
In view of the recent clinical successes of targeted mAbs to tumor antigens 
expressed on the surface of tumors for cancer therapy (3-5), we explored the 
feasibility to extend this approach of targeted mAb therapy to intracellular 
molecules as the majority of tumor antigens identified to date, are exclusively 
expressed and located inside the cell (14-16). Appropriate maneuvers that 
facilitate access of mAbs to these intracellular antigenic targets are critical 
requirement for this approach. Nucleoside analogues, such as 5-FU, 
predominantly induce apoptosis in target cells (31), but we found that 
NY-ESO-1 protein was released from tumor cells after 5-FU treatment in 
similar amounts as released by necrosis. The injected mAb accumulated into 
CT26-NY-ESO-1 tumors, suggesting the in vivo formation of antigen-Ab ICs. 
Furthermore, DCs in dLN that captured these ICs exhibited a mature 
phenotype and were associated with the induction of higher numbers of 
NY-ESO-1-specific CD8+ T cells. This augmented anti-tumor immunity by 
combination treatment with anti-NY-ESO-1 mAb and 5-FU was abrogated in 
nude mice and by deleting CD8+ cells, arguing that a major involvement of 
Ab-dependent cellular cytotoxicity (ADCC) or complement is less likely. 
Furthermore, this augmented anti-tumor effect by intracellular antigen-specific 
mAb combined with chemotherapy was observed in another tumor system 
using doxorubicin, indicating the broader application of this combination 
treatment. 
 A combination of anti-Her2 mAb and HER2/neu-expressing 
GM-CSF-secreting tumor vaccine augmented the anti-tumor effect compared 
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with either treatment alone, and the improved therapeutic efficacy depended 
on Fc-mediated activation of APCs (11). TA-99 (recognizing Trp1) mAb 
enhanced DNA vaccination-induced anti-tumor effects (12). More recently, 
Park et al. showed that the therapeutic effect of an anti-HER2/neu mAb was 
associated with adaptive cellular immune responses, such as CD8+ T cells 
(13). While these data clearly implicated a critical role for Fc-mediated APC 
activation and cross-priming correlated with enhancement of antigen-specific 
CD8+ T cell induction, other or additional mechanisms may include direct 
signal blocking and other Fc-mediated anti-tumor effects as the target antigens 
were expressed on the cell surface. These data, therefore, do not 
unambiguously suggest a possible application of mAb therapy to intracellular 
molecules. Here, we show that Fc-mediated antigen-specific CD8+ T cell 
induction was an important element of mAb therapy using mAbs against tumor 
antigens that are exclusively expressed in the intracellular compartment and 
we suggest the potential application of targeted mAb therapy also to 
intracellular tumor antigens. As a result, it is of interest to re-address the 
correlation between anti-tumor effect of CD8+ T cell response and clinical 
response by Trastuzumab (anti-Her2/neu) treatment, as Trastzumab is able to 
enhance cross-presentation in vitro (32). 
 Another unique point in our study is that our mAb treatment targeting 
an intracellular antigen does not require in vitro formation of IC or a 
combination with antigen immunization, such as protein or DNA vaccines for 
the formation of antigen-Ab IC (10-12, 33). When the mAb was injected alone, 
an augmented anti-tumor effect was not observed in our model, suggesting the 
essential role of chemotherapy for releasing sufficient amounts of antigen to 
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form antigen-Ab IC. Other modalities for facilitating antigen release from 
tumors such as radiation therapy, cryo-ablation or other agents that may result 
in partial destruction of tumor cells could be applicable to this combination 
therapy. These results are particularly important for considering the clinical 
application of targeted mAb therapy because combinations of chemotherapy 
and mAbs have already been widely used in the clinic (3-5). Furthermore, 
combining a mAb therapy with protein or DNA cancer vaccines is very 
expensive and enormous effort is required to translate into the clinic. 
 CD4+ T cell help is necessary for a proper activation and a 
long-lasting memory formation of CD8+ T cells (34, 35). While combination 
treatment with anti-NY-ESO-1 mAb and chemotherapy provided an 
augmented anti-tumor efficacy and induced higher numbers of 
NY-ESO-1-specific CD8+ T cells with effector-memory type, these effects were 
dependent on CD8+ T cells, but not CD4+ T cells. One can envisage that since 
a major role of CD4+ T cells is to stimulate APCs, such as DCs to activate 
CD8+ T cells (licensing) (34, 35), signals provided through Fc receptors may 
compensate the CD4+ T cell help for stimulating/activating APCs. Alternatively, 
inflammation induced by anti-cancer drugs further supports the 
stimulating/activating of APCs. 
One intriguing question is why the combination of mAb and 5-FU 
exhibited a strong anti-tumor effect, despite a possible inhibitory signal through 
a subclass of IgG, namely IgG1 used in this study (8). Since we employed 
anti-NY-ESO-1 mAbs (mouse IgG1) for this combination therapy, IgG1 may 
show inhibitory function by activating inhibitory Fc receptor (7-9). Some 
protocols of anti-cancer chemotherapy induce the stimulation of immune 
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responses by Toll-like receptor ligands released from tumor cells (36). The 
possibility that 5-FU-induced tumor destruction stimulates inflammation signals, 
such as Toll-like receptor signals, and these inflammation signals may change 
the ratio of stimulatory/inhibitory Fc receptor expression to a more stimulatory 
condition (8) is less likely, because our preliminary data shows that the 
balance between activating Fcγ receptor III and inhibitory Fcγ receptor IIB 
expression on CD11c+ cells was not influenced by 5-FU treatment. This raises 
several possibilities; 1) The balance between those receptors changes on 
other hematopoietic cells, 2). Signaling pathways through those Fcγ receptors 
are altered by chemotherapy-induced inflammation, 3). Ab specificity is not 
good enough to address this point and proper knockout animals are required. 
In addition, it will be crucial to compare the effect of immunological responses 
by other IgG subclasses, and studies with class-switched Abs and with Fcγ 
receptor IIB knockout mice are planned. 
 We observed that mAb and 5-FU combination treatment resulted in 
the development of an immune response against tumor antigens that have not 
been directly targeted by the Ab but that are expressed in tumor cells, a 
phenomenon known as antigen spreading (22, 29, 30). While mice treated with 
5-FU alone or without treatment elicited NY-ESO-1-specific CD8+ T cell 
responses, antigen spreading and its therapeutic effectiveness were limited in 
these mice. It is also possible that efficient activation of DCs by the targeted 
mAb and 5-FU combination treatment provides the opportunity to stimulate 
subsequently additional CD8+ T cells specific for other antigens derived from 
the tumor cells. Therefore, effective anti-tumor responses, such as tumor 
eradication, may require CD8+ T cells specific for the single antigen used for 
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immunization, but also multiple antigens that were contained in tumors, as 
shown in other murine systems and human cancer vaccines (1, 22, 37, 38). 
In our model as well as in cancer patients, NY-ESO-1 humoral 
responses could be spontaneously elicited. While a correlation between 
humoral responses and longer survival was not reported, NY-ESO-1-specific 
CD8+ T cell induction by cross-priming in vivo is associated with the induction 
of specific Abs (2, 39). Spontaneous NY-ESO-1 humoral responses are 
correlated with progression of tumor stage in humans (2, 39). In our mouse 
system, spontaneously-induced anti-NY-ESO-1 Abs were observed when 
tumors reached a larger size. The level of spontaneously-induced Abs is about 
10-times lower than that achieved by mAb injection (Supplemental Figure 1C), 
suggesting that spontaneously-induced humoral responses may potentially 
have some anti-tumor effects, but the amount of Abs may be too low to exhibit 
effective anti-tumor activity, such as facilitating tumor regression. Our data 
revealed that mAb and 5-FU combination treatment induced higher numbers of 
effector/memory NY-ESO-1-specific CD8+ T cells compared with 
chemotherapy alone, reflecting a long lasting anti-tumor capacity as shown by 
improved survival. In conclusion, combination treatment with targeted mAbs 
and chemotherapy opens a new era of Ab cancer immunotherapy for tumor 
antigens with intracellular expression. 
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Figure Legends 
 
Figure 1. Combination of mAb and an anti-cancer drug exhibits 
augmented tumor growth inhibition. 
(A-D, G) BALB/c mice were inoculated with CT26-NY-ESO-1 and treatment 
was started when tumors were palpable (around 25 mm2, day 5-7). Mice 
received 5-FU intravenously (black arrow) and/or anti-NY-ESO-1 mAb (clone; 
E978 or ES121) or anti-MAGE-A4 mAb (clone; MCV1) two days after 5-FU 
injection (red arrow). Treatment was repeated twice at one-week intervals. (A) 
Left panel: tumor growth curves representative of two independent 
experiments, right panel: summary of tumor size on day 24 of two independent 
experiments. (B) Survival curves summarized from another 3 independent 
experiments (separate from tumor growth data) are shown. (C, D) Left panels: 
tumor growth curves representative of two independent experiments, right 
panels: summary of tumor size of two independent experiments on day 23 and 
on day 21, respectively. (E) BALB/c mice were inoculated with 
CT26-MAGE-A4 and treatment was started as in (A). Mice received 5-FU 
(black arrow) and anti-MAGE-A4 mAb (clone; MCV1) or anti-NY-ESO-1 mAb 
(clone; E978) two days after 5-FU injection (red arrow). Left panel: tumor 
growth curves representative of two independent experiments, right panel: 
summary of tumor size on day 23 of two independent experiments. (F) BALB/c 
mice were inoculated with CMS5a-NY-ESO-1 and treatment was started as in 
(A). Mice received doxorubicin (50 μl, 0.25mM) intratumorally (black arrow) 
and/or anti-NY-ESO-1 mAb (clone; E978) two and four days after doxorubicin 
administration (red arrow). Left panel: tumor growth curves representative of 
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two independent experiments, right panel: summary of tumor size on day 21 of 
two independent experiments. (G) Mice were injected with 5-FU (black arrow) 
and anti-NY-ESO-1 mAb (E978, 100 µg) or cocktail of two anti-NY-ESO-1 
mAbs (E978 50 µg and ES121 50 µg) two days after 5-FU injection (red arrow). 
Left panel: tumor growth curves representative of two independent 
experiments, right panel: summary of tumor size on day 24 of two independent 
experiments. Tumor size was monitored three times a week. Each group 
consisted of 3-8 mice. Data are mean ±SD. N.S.: not significant. 
 
Figure 2. Augmented tumor growth inhibition by the combination 
treatment depends on CD8+ T cells. 
(A) BALB/cnu/nu mice were inoculated with CT26-NY-ESO-1 and treatment with 
5-FU (day 5 and 12, black arrow) and anti-NY-ESO-1 mAb (E978, day 7 and 
14, red arrow) was started as in Figure 1A. Left panel: tumor growth curves 
representative of two independent experiments, right panel: summary of tumor 
size on day 19 of two independent experiments. (B) BALB/c mice bearing 
CT26-NY-ESO-1 were injected with 5-FU (day 7 and 14, black arrow) and 
anti-NY-ESO-1 mAb (E978, day 9 and 16, red arrow), and received anti-CD4 
(day 7, 14 and 21, brown arrow) or anti-CD8 mAb (day 7 and 21, purple arrow), 
resulting in > 95% depletion of CD4/CD8 cell depletion. Left panel: tumor 
growth curves representative of two independent experiments, right panel: 
summary of tumor size on day 23 of two independent experiments. Tumor size 
was monitored three times a week. Each group consisted of 5-7 mice. Data 
are mean ±SD. N.S.: not significant. 
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Figure 3. Combination treatment enhances NY-ESO-1-specific CD8+ T 
cell induction. 
 (A B, and C) BALB/c mice (n=3) were inoculated with CT26-NY-ESO-1 and 
injected with 5-FU and anti-NY-ESO-1 mAb (E978). (A) On day 14, dLN were 
removed and incubated with NY-ESO-181-88 or control peptide. IFN-γ and 
TNF-α secretion by CD8+ T cells was analyzed. (B) dLN cells were isolated on 
day 16, and CD45RB and CD62L expression on NY-ESO-181-88-specific CD8+ 
T cells identified as CD8+NY-ESO-181-88/Dd tetramer+ T cells was analyzed. (C) 
Tumor infiltrating lymphocytes were collected on day 16, and incubated with 
NY-ESO-181-88 or control peptide. IFN-γ and TNF-α secretion by CD8+ T cells 
was analyzed. These experiments were repeated twice with similar results. 
Data are mean ±SD. EM: effector/memory T cells. 
 
Figure 4. Antigen spreading is observed in mice that received the 
combination treatment. 
BALB/c mice (n=3) were inoculated with CT26-NY-ESO-1 and injected with 
5-FU and anti-NY-ESO-1 mAb (E978). On day 24, dLN were removed and 
incubated with AH-1138-147 or control peptide. IFN-γ and TNF-α secretion by 
CD8+ T cells was analyzed. These experiments were repeated twice with 
similar results. Data are mean ±SD. 
 
Figure 5. The Fc receptor signals are required for augmented anti-tumor 
effects by the combination treatment. 
(A) BALB/c mice were inoculated with CT26-NY-ESO-1 and injected with 5-FU 
(day 7 and 14) and intact or Fc-depleted Fab anti-NY-ESO-1 mAb (E978, day 
on March 14, 2014. © 2012 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 8, 2012; DOI: 10.1158/0008-5472.CAN-11-3072 
 Noguchi et al. Antibody therapy to intracellular antigens 
  31
9 and 16). (B) Fcγ receptor knockout mice were inoculated with 
CT26-NY-ESO-1 and injected with 5-FU (day 7 and 14) and anti-NY-ESO-1 
mAb (E978, day 9 and 16). Tumor size was monitored three times a week. 
Each group consisted of 3-10 mice. Left panels: tumor growth curves 
representative of two independent experiments, right panels: summary of 
tumor size of two independent experiments on day 22 (A) and day 23(B). Data 
are mean ±SD. N.S.: not significant. 
 
Figure 6. The combination treatment results in accumulation of injected 
antibody at the tumor site and induces maturation of DCs. 
(A) BALB/c mice were inoculated with CT26-NY-ESO-1 and injected with 5-FU 
(day 5) and human anti-NY-ESO-1 mAb (12D7, day 7) or human anti-A33 mAb 
as a control (day 7). 24 hrs after mAb injection, tumors were removed and the 
accumulation of human anti-NY-ESO-1 mAb into tumors was examined by 
immunohistochemistry. (bar=50 µm) (B) CT26-NY-ESO-1 tumors as in (A) 
were removed at the indicated time points after mAb injection and co-stained 
with anti-human IgG mAb (green) and anti-cleaved caspase 3 mAb (red). 
(bar=50 µm) (C) Two days after the last 5-FU injection, dLN were harvested. 
CD80, CD86, CD40 and MHC class II expression on CD11chighDCs was 
analyzed. These experiments were repeated twice with similar results. 
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